Search - tctmd.com

Displaying 461 - 480 of 1124

Sort: Relevancy | Date

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

News Conference News TCT 2019

No Safety Signal Seen for CTO PCI at 3 Years: EUROCTO

Yael L. Maxwell

September 29, 2019

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

Post-MI Mechanical Complications Infrequent but Deadly

News Daily News

Post-MI Mechanical Complications Infrequent but Deadly

September 16, 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

September 01, 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

News Conference News ESC 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

Michael O'Riordan

September 01, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

News Daily News

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

August 30, 2019

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

August 23, 2019

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.